FSD Pharma Inc. Stock price

Equities

HUGE

CA35954B4047

Biotechnology & Medical Research

Market Closed - Canadian Securities Exchange 03:53:56 2024-03-28 pm EDT 5-day change 1st Jan Change
0.96 CAD 0.00% Intraday chart for FSD Pharma Inc. 0.00% -20.00%
Sales 2021 - Sales 2022 - Capitalization 29.53M 40.02M
Net income 2021 -35M -47.43M Net income 2022 -23M -31.17M EV / Sales 2021 -
Net cash position 2021 34.86M 47.24M Net cash position 2022 16.46M 22.31M EV / Sales 2022 -
P/E ratio 2021
-1.03 x
P/E ratio 2022
-1.26 x
Employees 17
Yield 2021 *
-
Yield 2022
-
Free-Float 82.48%
More Fundamentals * Assessed data
Dynamic Chart
FSD Pharma Edging Up In US Premarket Trade As Signs Agreement With iNGENu CRO MT
FSD Pharma Brief: Signed Agreement With iNGENu CRO To Conduct a Clinical Study To Assess Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy Adults MT
FSD Pharma Brief: Submitting a Phase-1b Clinical Trial Application for its Proprietary Beverage unbuzzd MT
FSD Pharma Inc. Submits A Phase-1B Clinical Trial Application for Ethics Committee for Its Proprietary Beverage Unbuzzd CI
FSD Pharma Presents "Positive" Phase 1 Lucid-21-302 Results at ACTRIMS Forum MT
Refile-- FSD Pharma Brief: Presenting "Positive" Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum MT
FSD Pharma Brief: Presenting "Positive: Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 Forum MT
FSD Pharma Inc. Presents Positive Results on First-In-Human Phase-1 Study of Lucid-21-302 (Lucid-Ms) At Americas Committee for Treatment and Research in Multiple Sclerosis 2024 Forum CI
MT Newswires Canada Stocks To Watch: SSR Mining, Tricon Residential; Imperial Oil; FSD Pharma MT
Reflile: FSD Pharma Up 3.7% In US Premarket As Says Court of Appeal Dismissed Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Near $3 Million MT
FSD Pharma Up 3.7$ In US Premarket As Says Court of Appeal Dismissed Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Near $3 Million MT
FSD Pharma Brief: Says Court of Appeal Dismissed Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Approximately $3 Million MT
FSD Pharma Inc. Announces Board Changes CI
FSD Pharma Files Final Base Shelf Prospectus to Replace Expired Base Shelf Prospectus MT
FSD Pharma Inc. announced that it has received CAD 0.000046 million in funding CI
More news
Current month-20.00%
1 month-22.58%
3 months-20.00%
6 months-40.74%
Current year-20.00%
More quotes
1 week
0.85
Extreme 0.85
0.98
1 month
0.85
Extreme 0.85
1.26
Current year
0.85
Extreme 0.85
1.48
1 year
0.85
Extreme 0.85
2.83
3 years
0.85
Extreme 0.85
2.83
5 years
0.85
Extreme 0.85
63.32
10 years
0.85
Extreme 0.85
188.94
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 94-10-19
Founder 47 94-10-19
Director of Finance/CFO 43 19-12-31
Members of the board TitleAgeSince
Founder 47 94-10-19
Chief Operating Officer 48 18-06-30
Director/Board Member 53 22-11-24
More insiders
Date Price Change Volume
24-03-28 0.96 +1.05% 9,363
24-03-27 0.95 -1.04% 29,093
24-03-26 0.96 +7.87% 218,786
24-03-25 0.89 -3.26% 21,143
24-03-22 0.92 -4.17% 24,374

Delayed Quote Canadian Securities Exchange, March 28, 2024 at 03:53 pm EDT

More quotes
FSD Pharma Inc. is a Canada-based biotechnology company. The Company operates through two segments: Biotechnology and Strategic Investments. Its Biotechnology segment is focused on furthering the research and development of the Company’s two primary drug candidates consisting of Lucid-MS and Lucid-PSYCH, as well as the development of UNBUZZD. The Company’s Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial real estate property. Lucid-PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. UNBUZZD is a proprietary formulation of natural ingredients, vitamins, and minerals to help with liver and brain function for the purposes of potentially quickly relieving from the effects of alcohol consumption, such as inebriation, and restoring normal lifestyle.
More about the company
  1. Stock
  2. Equities
  3. Stock FSD Pharma Inc. - Canadian Securities Exchange